Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001127602-16-062200)

Filing Details

Accession Number:
0001127602-16-062200
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-09-08 13:35:23
Reporting Period:
2016-09-06
Filing Date:
2016-09-08
Accepted Time:
2016-09-08 13:35:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
882095 Gilead Sciences Inc GILD Biological Products, (No Disgnostic Substances) (2836) 943047598
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1191589 F John Milligan Gilead Sciences, Inc.
333 Lakeside Drive
Foster City CA 94404		 President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-09-06 70,000 $20.74 1,128,963 No 4 M Direct
Common Stock Disposition 2016-09-06 70,000 $77.74 1,058,963 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-qualified Stock Option (Right to Buy) Disposition 2016-09-06 70,000 $0.00 70,000 $20.74
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2017-05-08 No 4 M Direct
Footnotes
  1. The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
  2. Options vest over a five year period beginning 5/08/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 5/08/2012.
  3. Sale prices reported for the transactions reported here range from $77.265 to $77.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.